Search - tctmd.com

Displaying 181 - 200 of 217

Sort: Relevancy | Date

News Daily News

‘Top Ten’ Advances of 2012 Highlighted by AHA-ASA, ACC

Caitlin E. Cox

December 26, 2012

News Industry News

One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial Published in Circulation

December 16, 2012

News Daily News

Un Modelo Confirma la Rentabilidad de la Denervación Renal en Varones y Mujeres

L.A. McKeown

December 02, 2012

News Daily News

Model Shows Cost-Effectiveness of Renal Denervation in Men, Women

L.A. McKeown

December 02, 2012

News Conference News AHA 2012

Early Study Shows Positive Clinical Results with Novel Renal Denervation Device

Jason Kahn

November 04, 2012

News Conference News TCT 2012

More Data Needed on Renal Denervation

October 25, 2012

News Conference News TCT 2012

Experts Discuss Future of Renal Denervation

October 25, 2012

Presentation TCT 2012

Lessons Learned Using the Symplicity Catheter 2: Complex Anatomy and Case Selection

Presenter: Erwin Blessing

October 24, 2012

Presentation TCT 2012

Three-Year Results from SYMPLICITY HTN-1 and SYMPLICITY HTN-2: What the Data Do (and Don't) Tell Us

Presenter: Michael Bohm

October 24, 2012

Presentation TCT 2012

SYMPLICITY Results Are Too Good to Be True: That's Why We Need a Sham Trial Design!

Presenter: Darrel Francis

October 24, 2012

Presentation TCT 2012

Lessons Learned Using the Symplicity Catheter 1: Procedural Do's and Don'ts

Presenter: Andreas Baumbach

October 24, 2012

News Industry News

Two-Year Follow-Up Of Symplicity Htn-1 Data Confirms Significant And Sustained Blood Pressure Reduction In Expanded Cohort Of Patients

October 22, 2012

News Industry News

Medtronic Completes First-In-Man Study for Investigational Next-Generation Multi-Electrode Renal Denervation System in Patients with Treatment-Resistant Hypertension

October 03, 2012

News Industry News

Medtronic Initiates First Clinical Trial of the Symplicity™ Renal Denervation System for Treatment-Resistant Hypertension in Japan

October 01, 2012

News Daily News

Un Modelo Sugiere que la Denervación Renal es Rentable contra la Hipertensión Resistente

September 13, 2012

News Daily News

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

September 13, 2012

News Industry News

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

September 12, 2012

News Daily News

Renal Denervation Reduces A-fib Recurrences in Small Study

Jason Kahn

September 07, 2012

News Daily News

La Denervación Renal Reduce las Recurrencias de la FA en un Pequeño Estudio

Jason Kahn

September 07, 2012

News Conference News ESC 2012

Renal Denervation Shows Promise for Heart Failure, Ongoing Success Against Hypertension

August 29, 2012

Advertisement

‘Top Ten’ Advances of 2012 Highlighted by AHA-ASA, ACC

One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial Published in Circulation

Un Modelo Confirma la Rentabilidad de la Denervación Renal en Varones y Mujeres

Model Shows Cost-Effectiveness of Renal Denervation in Men, Women

Early Study Shows Positive Clinical Results with Novel Renal Denervation Device

More Data Needed on Renal Denervation

Experts Discuss Future of Renal Denervation

Lessons Learned Using the Symplicity Catheter 2: Complex Anatomy and Case Selection

Three-Year Results from SYMPLICITY HTN-1 and SYMPLICITY HTN-2: What the Data Do (and Don't) Tell Us

SYMPLICITY Results Are Too Good to Be True: That's Why We Need a Sham Trial Design!

Lessons Learned Using the Symplicity Catheter 1: Procedural Do's and Don'ts

Two-Year Follow-Up Of Symplicity Htn-1 Data Confirms Significant And Sustained Blood Pressure Reduction In Expanded Cohort Of Patients

Medtronic Completes First-In-Man Study for Investigational Next-Generation Multi-Electrode Renal Denervation System in Patients with Treatment-Resistant Hypertension

Medtronic Initiates First Clinical Trial of the Symplicity™ Renal Denervation System for Treatment-Resistant Hypertension in Japan

Un Modelo Sugiere que la Denervación Renal es Rentable contra la Hipertensión Resistente

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension

Renal Denervation Reduces A-fib Recurrences in Small Study

La Denervación Renal Reduce las Recurrencias de la FA en un Pequeño Estudio

Renal Denervation Shows Promise for Heart Failure, Ongoing Success Against Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content